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OBJECTIVE—Forkhead box O (FoxO) transcription factors
represent evolutionarily conserved targets of insulin signaling,
regulating metabolism and cellular differentiation in response to
changes in nutrient availability. Although the FoxO1 isoform is
known to play a key role in adipogenesis, its physiological role in
differentiated adipose tissue remains unclear.
RESEARCH DESIGN AND METHODS—In this study, we
analyzed the phenotype of FoxO1 haploinsufﬁcient mice to
investigate the role of FoxO1 in high-fat diet–induced obesity and
adipose tissue metabolism.
RESULTS—We showed that reduced FoxO1 expression pro-
tects mice against obesity-related insulin resistance with marked
improvement not only in hepatic insulin sensitivity but also in
skeletal muscle insulin action. FoxO1 haploinsufﬁciency also
resulted in increased peroxisome proliferator–activated receptor
(PPAR) gene expression in adipose tissue, with enhanced
expression of PPAR target genes known to inﬂuence metabo-
lism. Moreover, treatment of mice with the PPAR agonist
rosiglitazone caused a greater improvement in in vivo insulin
sensitivity in FoxO1 haploinsufﬁcient animals, including reduc-
tions in circulating proinﬂammatory cytokines.
CONCLUSIONS—These ﬁndings indicate that FoxO1 proteins
negatively regulate insulin action and that their effect may be
explained, at least in part, by inhibition of PPAR function.
Diabetes 58:1275–1282, 2009
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dipose tissue is the body’s largest endocrine
organ, representing a complex, essential, and
highly active metabolic site of insulin action.
Moreover, excess adiposity, or obesity, is asso-
ciated with insulin resistance, hyperglycemia, dyslipide-
mia, and hypertension. Deciphering how vertebrates
integrate both intracellular and extracellular cues to reg-
ulate metabolism in adipose tissue may be central to
understanding the metabolic complications associated
with obesity.
The O subfamily of forkhead box (Fox) transcription
factors are direct targets of insulin action, regulating
cellular metabolism and survival in response to nutrient
and environmental stress. In addition, FoxO proteins
appear to play pivotal roles in the transcriptional cascades
that control differentiation in preadipocytes, myoblasts,
and endothelial cells (1). FoxO1 represents the predomi-
nant FoxO isoform present in both white and brown
adipose tissue. In preadipocytes, FoxO1 expression occurs
before the expression of peroxisome proliferator–acti-
vated receptor (PPAR), and tight temporal regulation of
its activity is required for differentiation to proceed. For
example, ectopic nuclear expression of FoxO1 via trans-
duction of constitutively active FoxO1 mutants results in
the inhibition of adipogenesis (2). Although complete
FoxO1 ablation causes embryonic lethality in vivo, FoxO1
haploinsufﬁciency yields viable offspring and restores nor-
mal insulin sensitivity in genetic models of insulin resis-
tance (3). In addition, FoxO1 haploinsufﬁciency has been
reported to reduce cell size and increase cell numbers of
adipocytes under a high-fat diet (HFD) (2). However, little
is known regarding the physiological role of FoxO1 in fully
differentiated adipose tissue.
The PPAR nuclear receptor plays a crucial role in
adipocyte metabolism and survival (4). Activation of
PPAR in the early phases of adipogenesis is well charac-
terized and is considered an absolute requirement for adipo-
cyte differentiation, controlling the subsequent expression of
adipocyte-speciﬁc genes involved in lipid storage and meta-
bolic control. The antidiabetes thiazolidinedione (TZD) drugs
have been identiﬁed as synthetic ligands of PPAR, exerting
potent effects to improve insulin action (4). PPARactivation
in peripheral tissues is now established as a well-recognized
approach to enhance insulin sensitivity, although the mech-
anism of action is only partially understood (5).
The convergence of FoxO1 and PPAR signaling path-
ways may represent an important mechanism regulating
energy homeostasis and insulin sensitivity in obesity.
Their differing roles in adipogenesis (2,4) suggest that
these two transcription factors also possess opposing
roles in the metabolic control of mature adipocytes as
well. We, therefore, hypothesized that FoxO1 might ham-
per PPAR activity and that inhibition of FoxO1 may lead
to improved insulin sensitivity, particularly in response to
treatment with PPAR ligand. To date, only a few prece-
dents for the convergence of FoxO1 and PPAR exist in
mammalian systems (6,7), and no studies have yet shown
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DIABETES, VOL. 58, JUNE 2009 1275their interaction in vivo. In this study, we demonstrate that
FoxO1 haploinsufﬁciency leads to a reduction in insulin
resistance induced by HFD, with improvements in PPAR
expression and activity.
RESEARCH DESIGN AND METHODS
Mutant mice. Generation of the targeted Foxo1 allele has been described (8).
Because the homozygous FoxO1 deletion is embryonic lethal, only heterozy-
gous mice were used. Male mice (aged 4 months) were fed a HFD for 4–24
weeks with 45% kcal from fat (Harlan Teklad Custom Diets). Mice treated with
TZD were fed rosiglitazone (3 g/day) blended into the same HFD. All mice
were maintained on a C57BL/6 background, and wild-type littermates were
used as controls. All mouse procedures conformed to the Guide for Care and
Use of Laboratory Animals of the National Institutes of Health and were
approved by the Animal Subjects Committee of the University of California,
San Diego.
Phenotypic evaluation of mice. We studied male Foxo1
/– and wild-type
mice, with or without TZD treatment (3 mg  kg
1  day
1 rosiglitazone). Body
weight measurements were obtained weekly. Whole blood was collected, and
the plasma was withdrawn for subsequent analysis of glucose, insulin, and
free fatty acids (FFAs). Plasma cytokines were measured by the core
laboratories of the Diabetes and Endocrinology Research Consortium (Uni-
versity of California, Los Angeles, CA).
Glucose and insulin tolerance tests. Mice were fasted for 6 h, followed by
injection with dextrose (1 g/kg) or regular human insulin (0.35 unit/kg) into
the peritoneal cavity. Blood samples were drawn by tail vein sampling at 0, 15,
30, 60, 90, and 120 min for glucose and/or insulin measurement.
Hyperinsulinemic-euglycemic clamp studies. In two separate groups of
mice, aged 5 and 10 months, animals were implanted with two catheters that
were tunneled subcutaneously, exteriorized at the back of the neck, and
encased in Silastic tubing. Four days after surgery, animals were fasted for 6 h,
and clamp studies were performed. A basal blood sample was taken at 90
min and measured for glucose, insulin, and FFA levels. After this, a primed
constant infusion of 5.0 Ci/h (0.12 ml/h) of [3-
3H]D-glucose (NEN Life Science
Products) was initiated. At time 0, a basal blood sample was drawn for
determination of glucose-speciﬁc activity. After basal sampling, glucose (50%
dextrose) and insulin (12 mU  kg
1  min
1) plus tracer (5.0 Ci/h) infusions
were initiated simultaneously, and glucose levels were clamped at euglycemia
using a variable glucose infusion rate (GIR). Steady state was achieved when
blood glucose was successfully clamped, and the GIR was ﬁxed for a
minimum of 30 min. At the end of the clamp, a ﬁnal blood sample was taken
for the determination of tracer-speciﬁc activity. The insulin-stimulated glu-
cose disposal rate (IS-GDR) is equal to the total glucose disposal rate minus
the basal glucose turnover rate.
mRNA isolation and RT-PCR. mRNA was isolated using an RNeasy Mini Kit
(Qiagen). We reverse-transcribed RNA using a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems) and then performed real-time PCR
using an ABI 7300 system. Each reaction was measured in duplicate under
standard reaction conditions. SYBR Green oligonucleotides were used for
detection and quantiﬁcation of a given gene, expressed as the mRNA level
normalized to a standard housekeeping gene (glyceraldehyde-3-phosphate
dehydrogenase [GAPDH] or -actin) using the CT method. We performed
separate control experiments to ensure that the efﬁciencies of target and
reference ampliﬁcation were equal. The speciﬁcity of the PCR ampliﬁcation
was veriﬁed by melting curve analysis of the ﬁnal products using Opticon 3
software (Bio-Rad). Primer sequences used to amplify Ppar, Pck1, Pdk4,
Sorbs1, Glut4, F4/80, CD11c, GAPDH, and -actin are available upon request.
Histochemistry. Parafﬁn-embedded adipose tissue sections were stained
with MAC2 (Cedarlane Laboratories). Stained slides were subsequently cover-
slipped with 4,6-diamidino-2-phenylindole-containing mounting medium (Vec-
tor Laboratories). Adipocyte size and percentage of MAC2-positive crown-like
structures per ﬁeld were calculated as described previously (9,10).
Programmed array plate analysis. The array plate mRNA assay combined
a multiplexed nuclease protection assay with array detection, performed by
high-throughput genomics (11). Liver tissue homogenates were ﬁrst lysed in
the presence of probes binding target mRNA species. Upon addition of S1
nuclease, excess probes and unhybridized mRNA were degraded, such that
only mRNA:probe duplexes remained. Alkaline hydrolysis destroyed the
mRNA component of the duplexes, leaving probes intact. After the addition of
neutralization solution, the probes were transferred to a programmed array
plate containing a 16-element array at the bottom of each well. Each array
element comprised a position-speciﬁc anchor oligonucleotide. The binding
speciﬁcity of each of the 16 anchors was modiﬁed with a programming linker
oligonucleotide complementary at one end to an anchor and at the other end
to a nuclease protection probe. During a hybridization reaction, probes were
captured by an immobilized programming linker and then were labeled with a
detection linker oligonucleotide, which was in turn labeled with a detection
conjugate that incorporated peroxidase. Chemiluminescent substrate was
applied, and the enzyme-produced light was captured in a digital image. The
light intensity at each array element was used as a measure of the target
mRNA present in the original tissue lysate.
Immunoblotting. We carried out immunoblotting on liver, muscle, and
adipose tissues collected from fasted mice. After animals were anesthetized
by the intraperitoneal administration of a ketamine-xylazine-acepromazine
cocktail, the right epididymal fat pad and right hindlimb (gastrocnemius and
quadriceps) muscles were removed. Regular insulin (10 units/kg) was then
injected through the inferior vena cava, and sections of the liver and left
hindlimb muscles were taken at 1 and 3 min after insulin injection, respec-
tively. To measure Akt phosphorylation, solubilized extracts containing equal
amounts of tissue protein were immunoblotted with rabbit polyclonal anti-
bodies against either Akt or phospho-Ser
473 Akt (Cell Signaling Technology,
Beverly, MA), followed by second antibody detection. Immunoblots were
analyzed by densitometry, and the results expressed as arbitrary units.
Statistical analyses. All values are expressed as means  SE unless
otherwise noted. We used ANOVA to determine differences between groups,
and repeated-measures ANOVA testing for comparisons over time. P  0.05
was considered signiﬁcant.
RESULTS
FoxO1 haploinsufﬁcient mice are protected from
HFD-induced insulin resistance. To investigate the
functional role of FoxO1 in HFD-induced obesity,
Foxo1
/– and wild-type mice (4 months old) were fed a
45% HFD for 24–28 weeks. Whole-body weights did not
differ between Foxo1
/– mice and their wild-type litter-
mates (Table 1). Previous studies have shown no differ-
ences in glucose or insulin homeostasis between wild-type
and Foxo1
/– mice fed a normal chow diet (2).
FoxO1 haploinsufﬁcient mice exhibited a striking age-
related phenotype, developing enhanced insulin sensitivity
after 24 weeks of the HFD. Although we performed
intraperitoneal glucose and insulin tolerance tests every 4
weeks after initiation of the HFD, no signiﬁcant differ-
ences between genotypes emerged until 24 weeks. At this
point, Foxo1
/– mice demonstrated lower fasting blood
glucose (Foxo1
/– 160  5.2 mg/dl vs. wild type 193  9.6
mg/dl, P  0.01) and plasma insulin levels (Foxo1
/–
4.27  0.6 vs. wild type 8.11  1.7 mg/dl, P  0.05).
Accordingly, improved insulin sensitivity was observed in
Foxo1
/– mice in glucose tolerance tests, as evident by
reduced postabsorptive glucose and insulin values (Fig. 1A
and B). Consistent with these results, the glucose-lowering
effects of insulin were signiﬁcantly enhanced in HFD-fed
Foxo1
/– mice during insulin tolerance tests (Fig. 1C and
D). No differences in body weight were detected between
the two groups (Fig. 1E). Together, these data indicate an
age-dependent protection from HFD-induced insulin resis-
tance in Foxo1
/– mice, similar to previous published
reports (2).
Insulin sensitivity is enhanced in both liver and
skeletal muscle of FoxO1 haploinsufﬁcient mice. We
next examined tissue-speciﬁc insulin action by conducting
hyperinsulinemic-euglycemic clamp experiments at 10
months of age after 26 weeks of the HFD. These studies
further supported our glucose tolerance test (GTT) and
insulin tolerance test (ITT) ﬁndings with an almost two-
fold increase in the glucose infusion rate in Foxo1
/– mice
compared with controls (Foxo1
/– 48.6  7.9 vs. wild type
26.0  5.9 mg  kg
1  min
1, P  0.05) (Fig. 2A and
supplementary Fig. 1, available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db08-
1001/DC1). Foxo1
/– mice also demonstrated signiﬁcantly
lower rates of basal hepatic glucose output (Foxo1
/–
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1  min
1)a s
well as markedly improved insulin-stimulated suppression
of hepatic glucose output (Foxo1
/– 71.2  9.2 vs. wild
type 32.3  3.8%, P  0.05) (Fig. 2B). These data are
consistent with changes in gluconeogenic gene expression
shown previously after dominant-negative FoxO1 inactiva-
tion in hepatocytes (12–14). Skeletal muscle is the major
site of glucose uptake, and, interestingly, we observed a
marked improvement in skeletal muscle insulin sensitivity
of Foxo1
/– mice, as shown by 1.5- and 2-fold increases in
TABLE 1
Characteristics of Foxo1
/ mice fed a HFD  TZD
HFD
P
HFD  TZD
P Wild type Foxo1
/ Wild type Foxo1
/
n 10 14 5 6
Age (months) 10 10 5 5
Duration of diet (weeks) 24 24 5 5
Body weight (g) 41.8  0.9 41.6  1.0 NS 35.8  0.9 34.5  0.9 NS
Fasting blood glucose (mg/dl) 193  9.6 160  5.2 0.01 175  8.6 140  8.1 0.02
Fasting plasma insulin (mg/dl) 8.11  1.7 4.27  0.6 0.05 1.43  0.17 0.95  12 0.05
Fasting free fatty acids (mmol/l) 0.56  0.04 0.59  0.05 NS 0.54  0.03 0.54  0.03 NS
Plasma adiponectin (ng/ml) 6,827  415 5,318  372 0.03 10,329  1,386 11,425  2,066 NS
Plasma leptin (pg/ml) 16,059  2,382 14,320  605 NS 11,631  1,898 8,016  1,682 NS
Plasma monocyte chemoattractant protein-1
(pg/ml) 46.4  4.9 61.4  7.1 NS 39.9  10.5 21.1  5.8 NS
Plasma interleukin-6 (pg/ml) 17.4  2.4 11.4  1.7 0.05 9.8  5.6 4.2  0.6 NS
Plasma tumor necrosis factor-	 (pg/ml) 4.2  0.4 4.9  0.8 NS 3.0  0.5 5.3  0.5 0.01
Liver weight (g) 2.92  0.31 2.35  0.17 0.05 1.96  0.09 2.01  0.09 NS
Epididymal fat mass (g) 2.41  0.32 3.17  0.34 0.03 1.74  0.09 1.41  0.11 0.03
Liver triglyceride content (mg/g) 2.20  0.53 1.87  0.23 NS 1.48  0.40 1.36  0.23 NS
Adipocyte cell size (arbitrary units) 8,688  626 6,426  633 0.03 4,880  224 7,630  813 0.03
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FIG. 1. Metabolic characterization of HFD-fed Foxo1
/– mice. Meta-
bolic features of 10-month-old male mice after 24 weeks of a HFD (wild
type n  10; Foxo1
/– n  14). A and B: Whole-blood glucose and plasma
insulin during intraperitoneal glucose tolerance testing. C and D:
Insulin tolerance testing. Animals were fasted for 6 and 4 h before
GTTs and ITTs, respectively. Results are represented as both absolute
glucose values and percent glucose decrease from basal. Values repre-
sent mean glucose  SE. *P < 0.05 for Foxo1
/– versus wild-type. E:
Mice were weighed at the initiation of the HFD and then at 4-week
intervals up to 28 weeks of HFD duration. Values represent mean body
weight of at least 15 mice per genotype  SE. f, wild type; E, Foxo1
/–.
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FIG. 2. Improved liver and skeletal muscle insulin sensitivity in
Foxo1
/– mice. Hyperinsulinemic-euglycemic clamp studies were per-
formed in 10-month-old male mice after 26 weeks of a HFD (wild type
n  4; Foxo1
/– n  5). Foxo1
/– mice show increased GIRs. A:
Decreased basal hepatic glucose output (Foxo1
/– 5.94  1.93 vs. wild
type 11.82  1.95 mg/kg/min, P < 0.05) and improved insulin-stimu-
lated hepatic glucose suppression (B) when compared with wild-type
littermates. Foxo1
/– mice also demonstrate enhanced total Rd (C) and
IS-GDR (D). Values represent the means  SE. *P < 0.05.
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respectively, compared with wild-type controls.
Consistent with the improved insulin sensitivity found in
the clamp studies, Akt phosphorylation was signiﬁcantly
enhanced by fourfold in muscle and sixfold in liver of
Foxo1
/– mice after insulin stimulation (Fig. 3A and B). We
found no differences in the phosphorylation of the insulin
receptor, insulin receptor substrate (IRS)-1 or IRS-2 (data
not shown). Subsequent measurements of Glut4 gene
expression in skeletal muscle demonstrated a signiﬁcant
increase in Glut4 mRNA in both gastrocnemius (1.98-fold
increase, P  0.05) and quadriceps muscle (1.92-fold in-
crease, P 
 0.02) of HFD-fed Foxo1
/– mice, consistent with
the enhanced glucose disposal observed during the clamp
experiments (Fig. 3C).
To further investigate the FoxO1-mediated improve-
ment in hepatic insulin sensitivity, we used a 16-gene
microarray to measure the expression of liver genes. As
expected, gluconeogenic gene expression (Pck1 and
G6pc) was reduced in Foxo1
/– mice (Fig. 3D). In addition,
we observed a decrease in the expression of genes known
to regulate lipogenesis (Scd1, Srebp1c, Fasn, and Acc)
(Fig. 3E) after a 6-h fast. Although liver triglyceride
content appeared to be lower in Foxo1
/– mice (Foxo1
/–
1.87  0.23 vs. wild type 2.20  0.53 mg  dl
1  mg liver
tissue
1), this difference did not reach statistical signiﬁ-
cance. Plasma FFA levels were similar between genotypes
(data not shown).
FoxO1 haploinsufﬁciency affects PPAR activation in
white adipose tissue. FoxO1 is highly expressed in
preadipoctyes and is known to regulate adipocyte differ-
entiation. Of note, dominant-negative FoxO1 expression
promotes adipogenesis in insulin-receptor–deﬁcient cells
(2). FoxO1 has also been reported to regulate target genes
involved in apoptosis, cell cycle regulation, stress resis-
tance, and DNA repair. Histological analysis of epididymal
fat revealed that adipocyte cell size was signiﬁcantly
smaller in Foxo1
/– mice (Fig. 4A and B and supplemen-
tary Fig. 2, available in an online appendix), similar to
previous reports (2). However, epididymal fat pad weights
were 31% higher in the knockout mice (Fig. 4C) despite
similar body weights of HFD-fed Foxo1
/– and wild-type
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FIG. 3. Insulin action in liver and muscle of Foxo1
/– mice. A and B:
Enhanced signaling through the PI3K pathway in Foxo1
/– and wild-
type (WT) mice was determined by measuring Akt activity after insulin
injection into the inferior vena cava. Representative blots from quad-
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relative measures of Akt phosphorylation between samples. Quantita-
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gene expression in skeletal muscle. Relative mRNA amounts of Glut4
from quadriceps and gastrocnemius muscle of HFD-fed Foxo1
/– and
wild-type mice were measured using real-time PCR. D and E: Liver gene
expression analysis. Relative mRNA amounts of genes controlling
gluconeogenesis and lipogenesis were measured in fasted mice using a
16-gene microarray platform (wild type n  4; Foxo1
/– n  6). Values
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using real-time PCR to measure relative amounts of PPAR and PPAR
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/–.
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this adipose depot. FoxO1 has been shown to upregulate
mouse adiponectin gene expression by forming a tran-
scriptional complex with CCAAT/enhancer-binding pro-
tein 	 and binding to the adiponectin promoter in
differentiated adipocytes (15). Interestingly, plasma adi-
ponectin levels were 22% lower in FoxO1 haploinsufﬁcient
mice (Table 1), perhaps due to reduced FoxO1 binding at
the adiponectin promoter. Plasma leptin and free fatty
acid levels were unchanged (data not shown). Plasma
interleukin (IL)-6 levels were 35% lower in Foxo1
/– mice
(Table 1), but macrophage content did not differ based on
F4/80 staining of histological sections of adipose tissue
(data not shown).
Recent in vitro studies from our group and others
demonstrate that the FoxO1 transcription factor nega-
tively regulates PPAR promoter activity in cultured mam-
malian cells (6,7,16). Interestingly, we found that Pparg
mRNA expression levels were signiﬁcantly higher in white
adipose tissues of Foxo1
/– mice (Fig. 4D). Quantitative
PCR studies also revealed an increase in the expression of
Pck1, a PPAR target gene known to regulate glycerogen-
esis (Fig. 4E). Higher Pck1 activity could lead to increased
fatty acid reesteriﬁcation and obesity, consistent with our
observed increment in adiposity. We also detected
changes in the expression of other PPAR target genes
involved in glucose uptake and oxidation, with increased
mRNA levels of Sorbs1 (also known as CAP) and Pdk4 in
HFD-fed Foxo1
/– mice (Fig. 4F–G).
Reduced FoxO1 expression improves the response to
PPAR agonist treatment. The PPAR nuclear receptor
is a well-known molecular target in the treatment of
insulin resistance. To further investigate the interaction of
FoxO1 and PPAR in vivo, we treated Foxo1
/– and
wild-type mice with the PPAR agonist rosiglitazone. Both
groups (4 months old) were fed a 45% HFD with and
without rosiglitazone treatment for 4 weeks. Weight gain
was identical between genotypes (Fig. 5A).
Although FoxO1 haploinsufﬁcient mice showed en-
hanced insulin sensitivity after 24 weeks of a HFD com-
pared with that of wild-type mice (Fig. 1), both Foxo1
/–
and wild-type groups were similarly glucose intolerant and
insulin resistant after only 4 weeks of a HFD. TZD-treated
wild-type and Foxo1
/– mice exhibited lower fasting glu-
cose values (Table 1) with improved glucose tolerance
compared with HFD-fed controls (Fig. 5B). However,
TZD-treated Foxo1
/– mice demonstrated greater gains in
insulin sensitivity with lower glucose excursions after
glucose challenge (Fig. 5B) and lower basal insulin levels
(Table 1) compared with TZD-treated wild-type litter-
mates. Similar results were evident when the decline in
glucose levels was measured during an ITT, with greater
glucose-lowering effects of insulin in the Foxo1
/– mice
(Fig. 5C and D).
The expression of key gluconeogenic genes in liver was
measured in both Foxo1
/– and wild-type groups after
rosiglitazone treatment. TZD-treated Foxo1
/– mice
showed lower Pck1 and G6pc expression compared with
their wild-type controls (Fig. 5E), suggesting that de-
creased gluconeogenesis contributes to the lower glucose
values during glucose and insulin tolerance testing. In the
liver, the interaction of FoxO1 with PPAR coactivator 1	
(Pgc1	) serves to increase Pck1 and G6pc expression, in
cooperation with the cAMP response element-binding
protein binding protein coactivator TORC2 (17). Interest-
ingly, TZD-treated Foxo1
/– mice showed decreased ex-
pression of both Pgc1a and Torc2 (Fig. 5E). Lipogenic
gene expression (Scd1, Srebp1c, Fasn, and Acc) also
tended to be lower in fasted liver (Fig. 5F), although these
differences did not reach statistical signiﬁcance.
Although smaller adipocytes were identiﬁed in epididy-
mal fat pads of Foxo1
/– mice fed a HFD alone, the
opposite was observed in mice after TZD treatment, with
a 36% increase in adipocyte size in Foxo1
/– mice (Fig. 6A
and B). Adipose tissue macrophages increase in obesity,
localizing around adipocytes to form crown-like structures
(18). Macrophage inﬁltration into adipose tissue was at-
tenuated in TZD-treated Foxo1
/– mice, with a lower
percentage of adipocytes surrounded by MAC2-stained
cells (Foxo1
/– 2.0  0.7% vs. wild type 2.0  0.7%, P 

0.07) and decreased relative expression of F4/80 and
CD11c genes (F4/80: Foxo1
/– 1.0  0.47 vs. wild type
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FIG. 5. Effect of TZD treatment on in vivo glucose homeostasis and
insulin sensitivity in Foxo1
/– mice. A: Body weights of male mice were
measured at initiation of rosiglitazone treatment and every 4 weeks up
to 8 weeks of age (wild-type HFD  TZD n  8; Foxo1
/– HFD  TZD
n  10). B: Glucose tolerance testing (1 g/kg dextrose i.p.) was
performed on mice after 5 weeks of combined HFD and TZD (wild-type
HFD  TZD n  8; Foxo1
/– HFD  TZD n  10) and compared with
GTT results from mice after 5 weeks of the HFD alone (wild-type HFD
n  10; Foxo1
/– HFD n  14). Values represent mean glucose  SE. C
and D: Insulin tolerance testing (0.35 unit/kg insulin i.p.) was con-
ducted on mice after 5 weeks of combined HFD and TZD (HFD  TZD
wild type n  8; HFD Foxo1
/  TZD n  10) and compared with GTT
results from mice after 5 weeks of the HFD alone (HFD wild type n 
10; HFD Foxo1
/– n  14). Results are represented as both absolute
glucose values and percent glucose decrease from basal. Glucose
curves from both GTT and ITT were signiﬁcantly different between
TZD-treated Foxo1
/– and wild-type mice (P < 0.04) and between
TZD-treated Foxo1
/– mice compared with mice fed a HFD alone (P <
0.001). E, HFD Foxo1
/–; f, HFD wild type; E, HFD  TZD Foxo1
/–; f,
HFD  TZD wild type. E and F: Liver gene expression studies con-
ducted in TZD-treated Foxo1
/– mice used a programmed microarray
technique to measure genes that inﬂuence both hepatic glucose pro-
duction and fatty acid synthesis. Relative mRNA values are reported as
means  SE. *P < 0.05. AU, arbitrary units. f,F D TZD wild type; o,
HFD  TZD Foxo1
/–.
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/– 1.0  0.06 vs.
wild type 6.3  1.3 arbitrary units; P  0.05).
The enhanced response of Foxo1
/– mice to rosiglita-
zone, as seen by GTT and ITT, was further supported by
the TZD-induced decrease in levels of serum cytokines
associated with inﬂammation and insulin resistance (tu-
mor necrosis factor-	, IL-6, and monocyte chemoattrac-
tant protein-1) (Fig. 6C). PPAR ligand treatment leads to
increased adiponectin and decreased leptin concentra-
tions (19). Although serum adiponectin levels were higher
in both genotypes after TZD treatment, Foxo1
/– mice
showed a greater increment in adiponectin concentration,
compared with wild-type littermates (Fig. 6D). As ex-
pected, serum leptin levels were measurable in HFD-fed
wild-type mice. These levels decreased in both groups
after TZD administration, consistent with improved insulin
sensitivity, although a much greater decrease was ob-
served in Foxo1
/– mice (Fig. 6E). These data suggest that
decreased expression of FoxO1 potentiates TZD action in
vivo.
DISCUSSION
FoxO1 transcription factors serve as negative regulators of
insulin action, mediating key events in adipogenesis, myo-
genesis, and glucose homeostasis (20). FoxO proteins
localize to the nucleus, where they activate the transcrip-
tion of target genes. However, upon phosphorylation by
Akt, they are exported promptly to the cytoplasm, provid-
ing a direct mechanism for insulin-suppressed gene ex-
pression (1). Although the FoxO1 isoform has been shown
to promote the expression of key gluconeogenic enzymes
in liver (12,13,21), it is unclear how it contributes to
metabolism in other tissues, particularly adipose and
skeletal muscle. In addition, a clear interaction of FoxO1
with the PPAR nuclear receptor has not yet been dem-
onstrated in vivo. In this study, we show that reduced
expression of FoxO1 enhances insulin sensitivity, not only
in liver but also in skeletal muscle. In addition, FoxO1
haploinsufﬁciency is associated with increased expression
of PPAR and PPAR-dependent target genes in adipose
tissue and an improved response to PPAR agonist treat-
ment during consumption of a HFD.
FoxO1 haploinsufﬁciency has been shown to attenuate
insulin resistance in mice with mutations of the insulin
receptor and IRS-2 (3). Here, we demonstrate that FoxO1
heterozygosity confers protection against HFD-induced
insulin resistance, despite an increase in epididymal fat
mass. Furthermore, our euglycemic clamp studies are the
ﬁrst to measure hepatic glucose output directly in
Foxo1
/– mice and demonstrate improvements in both
basal and insulin-mediated suppression of hepatic glucose
production.
In the present study, we noted a decrease in liver size in
HFD-fed Foxo1
/– mice, with reductions in the hepatic
expression of Scd1, Srebp1c, Fasn, and Acc, suggesting
that FoxO1 promotes fatty acid synthesis in liver. Al-
though we cannot exclude secondary effects due to differ-
ences in circulating insulin between genotypes and the
presence of relative hyperinsulinemia in HFD-fed wild-
type mice, these results are consistent with prior obser-
vations linking FoxO1 to insulin-dependent hepatic
triglyceride production (21,22) and support the concept
that FoxO1 haploinsufﬁciency may suppress Srebp1c and
lipogenic gene expression in the liver when insulin signal-
ing is disrupted. Interestingly, prior studies in a transgenic
mouse expressing constitutively nuclear FoxO1 in liver
showed reduced cholesterol and triglyceride levels with a
decrease in lipogenic gene expression (23). This apparent
difference may be due to nutrient status, because our
Foxo1
/– animals were studied while fasting, whereas the
constitutively nuclear FoxO1 transgenic mouse was stud-
ied after refeeding. Consistent with prior studies in hepa-
tocytes under both in vitro and in vivo conditions, Pck1
and G6pc expression was reduced in Foxo1
/– mice.
The FoxO1 isoform is highly expressed in skeletal
muscle (3) and has been reported to control myocyte
differentiation (24). For example, conditional ablation of
FoxO1 in skeletal muscle leads to increased formation of
fast-twitch muscle ﬁbers (25), whereas FoxO1 overexpres-
sion leads to reduced skeletal muscle mass with a marked
decrease in slow-twitch ﬁbers (26). Transgenic FoxO1
overexpression in muscle has also been shown to reduce
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FIG. 6. Cytokine and adipokine proﬁling in TZD-treated Foxo1
/– mice.
A and B: Average size of adipocytes from epididymal fat (wild type n 
4; Foxo1
/– n  5). Representative photomicrographs are represented.
Scale bars represent 100 m. C–E. Multiplexed bead immunoassay
techniques were used to measure circulating cytokine and adipokine
levels in HFD-fed animals in the presence or absence of TZD. Proin-
ﬂammatory serum cytokines (tumor necrosis factor- [TNF-], IL-6,
and monocyte chemoattractant protein 1 [MCP-1]) are signiﬁcantly
reduced in TZD-treated Foxo1
/– mice. Although serum adiponectin
levels are lower in HFD-fed Foxo1
/– compared with HFD-fed wild-type,
FoxO1 haploinsufﬁciency is associated with higher elevations in serum
adiponectin after TZD treatment. In contrast, serum leptin values
decrease to a greater extent in TZD-treated Foxo1
/– animals. These
serum cytokine and adipokine data are also presented in numeric form
in Table 1. Values are reported as means  SE. *P < 0.05. f, HFD wild
type; , HFD Foxo1
/–; s, HFD  TZD wild type; o, HFD  TZD
Foxo1
/–.
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tolerance (26). Otherwise, little evidence has been re-
ported on the effect of FoxO1 on skeletal muscle metab-
olism. In this regard, our clamp data show that FoxO1
haploinsufﬁciency results in signiﬁcantly improved glu-
cose disposal despite obesity, with a robust increase in
insulin-stimulated muscle Akt phosphorylation. Although
some effects of FoxO1 may be indirect, these results
support the conclusion that FoxO1 plays a regulatory role
in skeletal muscle to modulate insulin sensitivity.
Of interest, although many murine models with het-
erozygous gene deletions do not exhibit a measurable
metabolic phenotype, Foxo1
/– mice show clear differ-
ences in glucose metabolism. In addition, these differences
are only apparent in older, obese HFD-fed Foxo1
/– mice
and not in younger mice or during feeding of normal chow
diets. Endogenous FoxO1 is largely dephosphorylated in
adipocytes after HFD, remaining localized to the nucleus
(27). Thus, the effects of FoxO1 may be greater in HFD-fed
animals because dephosphorylated FoxO1 proteins are
predominantly nuclear, and, therefore, transcriptionally
active. In the Foxo1
/– mouse model, improved insulin
sensitivity in concert with increased Akt phosphorylation
could produce higher levels of FoxO1 phosphorylation,
driving FoxO1 nuclear export in a feed-forward manner. In
turn, because these mice are haploinsufﬁcient, increased
nuclear export of FoxO1 could potentially result in near-
complete inactivation of FoxO1, resulting in a phenotype
that mimics homozygous deletion of the gene.
FoxO1 is the most abundant FoxO isoform identiﬁed in
both white and brown adipose tissues (2). Evidence from
several laboratories, including ours, suggests that FoxO1
interferes with PPAR activity in cultured adipocytes.
FoxO1 binds to both PPAR1 and PPAR2 promoters to
repress their transcriptional activity, leading to decreased
PPAR expression (6,7). In addition, we have recently
shown that FoxO1 binds directly to PPAR and disrupts its
DNA binding ability (16). Through this mechanism, FoxO1
may interfere with promoter DNA occupancy of the
PPAR receptor.
In this study, we provided additional evidence to sug-
gest that FoxO1 inhibits PPAR activity in vivo. Foxo1
/–
mice showed increased PPAR mRNA in white adipose
tissue, suggesting that FoxO1 inhibits PPAR gene expres-
sion. In addition, we measured mRNA levels of several
PPAR target genes and observed enhanced expression of
Pck1, Sorbs1, and Pdk4, genes known to participate in
glycerogenesis, glucose uptake, and oxidation. Interest-
ingly, FoxO1 has been shown to induce the expression of
PDK4 in both skeletal muscle and liver (28), but PDK4
mRNA was enhanced in adipose tissue in FoxO1 haploin-
sufﬁcient mice in the present study. This increase in
adipose Pdk4 may be secondary to increased PPAR
function with FoxO1 haploinsufﬁciency, as TZDs have
recently been shown to upregulate the expression of Pdk4
in adipocytes (29). Changes in the activity of PPAR could
account, in part, for the improved insulin sensitivity after
feeding of a HFD in Foxo1
/– mice.
These ﬁndings were further supported by our experi-
ments in TZD-treated animals. Administration of rosiglita-
zone to obese mice produced signiﬁcantly greater insulin
sensitivity in Foxo1
/– mice compared with wild-type
littermates. Reduced expression of FoxO1 with subse-
quent enhancement of PPAR transactivation could ac-
count for this ampliﬁed response to the PPAR agonist.
In conclusion, the present study demonstrates that
FoxO1 haploinsufﬁciency protects against HFD-induced
insulin resistance with improvements in both liver and
muscle insulin sensitivity. Adipose tissue of Foxo1
/– mice
also demonstrates increased expression of Ppar and its
target genes. Moreover, FoxO1 haploinsufﬁciency pro-
duces an enhanced response to PPAR agonist treatment.
These ﬁndings indicate that FoxO1 proteins negatively
regulate insulin action in obesity and that their effect may
be explained, at least in part, by inhibiting the activation of
PPAR.
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